Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction
Pedro A. Lemos, MD*,
Francesco Saia, MD*,
Sjoerd H. Hofma, MD*,
Joost Daemen*,
Andrew T. L. Ong, MBBS FRACP*,
Chourmouzios A. Arampatzis, MD*,
Angela Hoye, MBChB, MRCP*,
Eugene McFadden, MBChB, FRCPI, FACC*,
Georgios Sianos, MD, PhD*,
Pieter C. Smits, MD, PhD*,
Willem J. van der Giessen, MD, PhD*,
Pim de Feyter, MD, PhD, FACC*,
Ron T. van Domburg, PhD* and
Patrick W. Serruys, MD, PhD, FACC*,*
* Erasmus Medical Center, Thoraxcenter, Rotterdam, Netherlands
View larger version (21K):
[in a new window]
|
Figure 1 Survival free of reinfarction or target vessel revascularization in the sirolimus-eluting stent and conventional stent groups. CI = confidence interval.
|
|
|
